1. Gdf-15 deficiency does not alter vulnerability of nigrostriatal dopaminergic system in MPTP-intoxicated mice
- Author
-
Klaus Unsicker, Björn Spittau, Lioudmila Bogatyreva, Venissa Machado, Kerstin Krieglstein, Ralf Gilsbach, Richa Das, Andreas Schober, and Dieter Hauschke
- Subjects
0301 basic medicine ,pathology [Neostriatum] ,Parkinson's disease ,Endogeny ,Mice ,chemistry.chemical_compound ,0302 clinical medicine ,Neurotrophic factors ,metabolism [Growth Differentiation Factor 15] ,metabolism [Neostriatum] ,Microglia ,Chemistry ,MPTP ,metabolism [Dopaminergic Neurons] ,Dopaminergic ,deficiency [Growth Differentiation Factor 15] ,Gdf15 protein, mouse ,Substantia Nigra ,medicine.anatomical_structure ,1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine ,embryonic structures ,Cytokines ,Inflammation Mediators ,Neuroglia ,metabolism [Biomarkers] ,medicine.medical_specialty ,Growth Differentiation Factor 15 ,Histology ,metabolism [RNA, Messenger] ,Pathology and Forensic Medicine ,genetics [RNA, Messenger] ,03 medical and health sciences ,administration & dosage [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] ,Internal medicine ,metabolism [Substantia Nigra] ,medicine ,Animals ,ddc:610 ,RNA, Messenger ,metabolism [Neuroglia] ,pathology [Substantia Nigra] ,Cell Proliferation ,Dopaminergic Neurons ,metabolism [Inflammation Mediators] ,metabolism [Cytokines] ,Cell Biology ,medicine.disease ,Neostriatum ,030104 developmental biology ,Endocrinology ,nervous system ,Neuron ,Neuroscience ,Biomarkers ,030217 neurology & neurosurgery ,Transforming growth factor - Abstract
Growth/differentiation factor−15 (Gdf-15) is a member of the transforming growth factor-β (Tgf-β) superfamily and has been shown to be a potent neurotrophic factor for midbrain dopaminergic (DAergic) neurons both in vitro and in vivo. Gdf-15 has also been shown to be involved in inflammatory processes. The aim of this study was to identify the role of endogenous Gdf-15 in the MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model of Parkinson’s disease (PD) by comparing Gdf-15 +/+ and Gdf-15 −/− mice. At 4 days and 14 days post-MPTP administration, both Gdf-15 +/+ and Gdf-15 −/− mice showed a similar decline in DAergic neuron numbers and in striatal dopamine (DA) levels. This was followed by a comparable restorative phase at 90 days and 120 days, indicating that the absence of Gdf-15 does not affect the susceptibility or the recovery capacity of the nigrostriatal system after MPTP administration. The MPTP-induced microglial and astrocytic response was not significantly altered between the two genotypes. However, pro-inflammatory and anti-inflammatory cytokine profiling revealed the differential expression of markers in Gdf-15 +/+ and Gdf-15 −/− mice after MPTP administration. Thus, the MPTP mouse model fails to uncover a major role of endogenous Gdf-15 in the protection of MPTP-lesioned nigrostriatal DAergic neurons, in contrast to its capacity to protect the 6-hydroxydopamine-intoxicated nigrostriatal system.
- Published
- 2016
- Full Text
- View/download PDF